1. Home
  2. FTFT vs QTTB Comparison

FTFT vs QTTB Comparison

Compare FTFT & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Future FinTech Group Inc.

FTFT

Future FinTech Group Inc.

HOLD

Current Price

$1.06

Market Cap

22.0M

ML Signal

HOLD

Logo Q32 Bio Inc.

QTTB

Q32 Bio Inc.

HOLD

Current Price

$2.88

Market Cap

25.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTFT
QTTB
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.0M
25.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FTFT
QTTB
Price
$1.06
$2.88
Analyst Decision
Hold
Analyst Count
0
4
Target Price
N/A
$7.33
AVG Volume (30 Days)
109.0K
9.0M
Earning Date
11-14-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,665,719.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.01
$1.35
52 Week High
$5.00
$6.37

Technical Indicators

Market Signals
Indicator
FTFT
QTTB
Relative Strength Index (RSI) 32.66 50.06
Support Level $0.95 $2.72
Resistance Level $1.32 $3.96
Average True Range (ATR) 0.11 0.54
MACD 0.01 -0.02
Stochastic Oscillator 12.56 20.00

Price Performance

Historical Comparison
FTFT
QTTB

About FTFT Future FinTech Group Inc.

Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.

About QTTB Q32 Bio Inc.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.

Share on Social Networks: